Non-small cell lung cancer

News

AZ takes aim at BMS' lead in neoadjuvant NSCLC

Just weeks after Bristol-Myers Squibb claimed an FDA green light for Opdivo as a neoadjuvant therapy for non-small cell lung cancer, AstraZeneca is looking to encroach on its territory.

News

Roche's Tecentriq extends lead over Keytruda in adjuvant NSC...

While Merck & Co's Keytruda is the undisputed leader of the non-small cell lung cancer (NSCLC) category, there's one category where it lags behind Roche's Tecentriq – treatment of early

News

Mirati heads for FDA verdict on KRAS drug with new data

Mirati Therapeutics will hear from the FDA on its KRAS inhibitor adagrasib later this year, hoping to compete with first-to-market rival Lumakras from Amgen.

News

Roche's TIGIT ambitions take another blow

Roche's anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its hopes of finding a companion to its cancer immunotherapy blockbuste

News

CHMP backs Roche's lymphoma bispecific mosunetuzumab

Roche is on the brink of its first regulatory approval for what could be the first bispecific antibody targeting CD3 and CD20 – mosunetuzumab – after getting a positive opinion for the drug

News

FDA starts speedy review of Enhertu in lung cancer

AstraZeneca and Daiichi Sankyo should only have to wait for six months to hear from the FDA if it will approve their HER2 drug Enhertu for non-small cell lung cancer (NSCLC) and add to its

AZ takes aim at BMS' lead in neoadjuvant NSCLC

Roche's Tecentriq extends lead over Keytruda in adjuvant NSC...

Mirati heads for FDA verdict on KRAS drug with new data

Roche's TIGIT ambitions take another blow

CHMP backs Roche's lymphoma bispecific mosunetuzumab

FDA starts speedy review of Enhertu in lung cancer

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

Non-small cell lung cancer

Editor's Picks